Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Table 2 Subgroup analysis of the relationship between the ALI and OS

Subgroup factor	Divided standard	No. of studies	HR (95% CI)	P	Heterogeneity
Subgroup factor	Divided standard	No. of studies	HR (95% CI)	P	I² (%)	P _het
Median age (years)	< 60	5	1.59 (1.24–1.95)	< 0.001	0.0	0.66
	≥ 60	2	2.59 (1.56–3.63)	< 0.001	0.0	0.637
	Not reported	2	1.70 (1.11–2.30)	< 0.001	52.9	0.145
Sample size	< 170	4	2.61 (1.69–3.52)	< 0.001	0.0	0.614
Sample size	≥ 170	5	1.60 (1.29–1.90)	< 0.001	0.0	0.749
Ethnicity	Asian	6	1.80 (1.43–2.18)	< 0.001	12	0.34
	European	2	2.29 (0.97–3.61)	NS	0.0	0.91
	North American	1	1.42 (1.00–2.01)	< 0.001	–	–
Pathological type	NSCLC	4	1.55 (1.08–2.02)	< 0.001	19.2	0.29
	SCLC	2	1.64 (1.24–2.05)	< 0.001	0.0	0.898
	Colorectal cancer	1	2.77 (1.77–4.34)	< 0.001	–	–
	Head and neck squamous cell carcinoma	1	2.23 (1.12–4.55)	0.011	–	–
	Diffuse large B cell lymphoma	1	2.64 (1.54–5.97)	0.019	–	–
Clinical stage	Metastatic	3	1.64 (1.18–2.10)	< 0.001	52.7	0.12
	Non-metastatic	2	2.50 (0.78–4.21)	NS	0.0	0.20
	Mixed	4	1.70 (1.31–2.09)	< 0.001	0.0	0.76
Treatment	Surgery	3	2.37 (1.15–3.58)	< 0.001	0.0	0.43
Treatment	No surgery	6	1.66 (1.36–1.96)	< 0.001	0.5	0.41
Cutoff of ALI	< 23.2	4	1.55 (1.19–1.92)	< 0.001	13.7	0.32
Cutoff of ALI	≥ 23.2	5	1.96 (1.47–2.44)	< 0.001	0.0	0.59

Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, Mixed included patients with metastatic and non-metastatic disease, ALI advanced lung cancer inflammation index, NS not significant

ISSN: 1477-7819